SC
EW icon

Salzman & Co’s Edwards Lifesciences EW Stock Holding History

Salzman & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,385,856
Closed -$16.1M – 4
2013
Q3 		$16.1M Sell
1,385,856
-572,820
-29% -$6.7M 14.39% 4
2013
Q2 		$21.9M Buy
+1,958,676
New +$23.2M 34.92% 2

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Salzman & Co's EW Position: Q4 2013 in Review

Salzman & Co sold out of Edwards Lifesciences (EW) in Q4 2013, closing a stake of 1,385,856 shares — an estimated $16.1M sold.

Salzman & Co first reported a position in EW in Q2 2013 and held it in 2 quarters. The position peaked at $21.9M in Q2 2013. 408 funds tracked by Wall St. Rank hold EW as of Q4 2013.

  • Salzman & Co reported no remaining Edwards Lifesciences position as of Q4 2013 after selling out during the quarter.
  • Salzman & Co sold 1,385,856 Edwards Lifesciences shares in Q4 2013, an estimated $16.1M.
  • Salzman & Co first reported a position in Edwards Lifesciences in Q2 2013 and held it in 2 quarters.
  • Salzman & Co's Edwards Lifesciences position peaked at $21.9M in Q2 2013.
  • 408 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2013.

Based on Salzman & Co's 13F filing for Q4 2013, filed 14 Feb 2014.